Latest news with #JohnHester
Business Insider
11-07-2025
- Business
- Business Insider
Bell Potter Remains a Buy on Telix Pharmaceuticals (TLPPF)
Bell Potter analyst John Hester maintained a Buy rating on Telix Pharmaceuticals today and set a price target of A$34.00. The company's shares closed today at $16.00. Don't Miss TipRanks' Half-Year Sale Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week. According to TipRanks, Hester is a 3-star analyst with an average return of 5.2% and a 51.58% success rate. Hester covers the Healthcare sector, focusing on stocks such as Telix Pharmaceuticals, Clarity Pharmaceuticals Ltd., and Paragon Care Limited. Currently, the analyst consensus on Telix Pharmaceuticals is a Strong Buy with an average price target of $22.08.
Business Insider
26-06-2025
- Business
- Business Insider
Bell Potter Remains a Buy on Paragon Care Limited (PXS)
Bell Potter analyst John Hester maintained a Buy rating on Paragon Care Limited (PXS – Research Report) today and set a price target of A$0.52. The company's shares closed last Monday at €0.21. Confident Investing Starts Here: Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter Hester covers the Healthcare sector, focusing on stocks such as Clarity Pharmaceuticals Ltd., Mesoblast Limited, and Telix Pharmaceuticals. According to TipRanks, Hester has an average return of 3.8% and a 46.74% success rate on recommended stocks. Paragon Care Limited has an analyst consensus of Moderate Buy, with a price target consensus of €0.29.
Business Insider
19-06-2025
- Business
- Business Insider
Bell Potter Remains a Buy on Clarity Pharmaceuticals Ltd. (CU6)
Bell Potter analyst John Hester maintained a Buy rating on Clarity Pharmaceuticals Ltd. (CU6 – Research Report) today and set a price target of A$4.90. The company's shares opened today at A$2.18. Confident Investing Starts Here: Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter Hester covers the Healthcare sector, focusing on stocks such as Clarity Pharmaceuticals Ltd., Mesoblast Limited, and Telix Pharmaceuticals. According to TipRanks, Hester has an average return of 4.3% and a 46.74% success rate on recommended stocks. Clarity Pharmaceuticals Ltd. has an analyst consensus of Strong Buy, with a price target consensus of A$6.15, a 182.11% upside from current levels. In a report released on June 15, Wilsons also maintained a Buy rating on the stock with a A$8.25 price target.
Business Insider
12-06-2025
- Business
- Business Insider
Bell Potter Remains a Buy on Radiopharm Theranostics Limited (RAD)
Bell Potter analyst John Hester maintained a Buy rating on Radiopharm Theranostics Limited (RAD – Research Report) today and set a price target of A$0.05. The company's shares closed today at A$0.03. Confident Investing Starts Here: According to TipRanks, Hester is a 4-star analyst with an average return of 7.3% and a 50.55% success rate. Hester covers the Healthcare sector, focusing on stocks such as Clarity Pharmaceuticals Ltd., Polynovo , and Mesoblast Limited. Currently, the analyst consensus on Radiopharm Theranostics Limited is a Moderate Buy with an average price target of A$0.05. The company has a one-year high of A$0.05 and a one-year low of A$0.02. Currently, Radiopharm Theranostics Limited has an average volume of 4.33M. Based on the recent corporate insider activity of 12 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of RAD in relation to earlier this year.
Business Insider
11-06-2025
- Business
- Business Insider
Bell Potter Sticks to Their Buy Rating for Clarity Pharmaceuticals Ltd. (CU6)
Bell Potter analyst John Hester maintained a Buy rating on Clarity Pharmaceuticals Ltd. (CU6 – Research Report) today and set a price target of A$4.90. The company's shares closed today at A$2.39. Confident Investing Starts Here: Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter According to TipRanks, Hester is a 4-star analyst with an average return of 7.2% and a 50.00% success rate. Hester covers the Healthcare sector, focusing on stocks such as Clarity Pharmaceuticals Ltd., Polynovo , and Mesoblast Limited. Currently, the analyst consensus on Clarity Pharmaceuticals Ltd. is a Strong Buy with an average price target of A$6.22, representing a 160.25% upside. In a report released on June 5, Canaccord Genuity also maintained a Buy rating on the stock with a A$6.74 price target.
